Abstract: the article analyzes forms of targeted therapy in the context of autoimmune pathologies. The molecular basis of modern targeted therapy – protein, DNA-analogs, protein-(DNA-analogs) constructs was outlined; genetic mechanisms of autoimmune pathologies. In relation to the latter, the use of bilateral targeted therapy is modeled and justified: antisense oligonucleotides are unique for each patient to block gene expression of the corresponding unique variable regions of autoreactive T and/or B lymphocytes.
Keywords: autoimmune pathologies, lymphocyte’s genomes variable regions, targeted therapy, bilateral targeted therapy, antisense oligonucleotides, artificially acquired personal passive genome immunity
151-159 p.